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Abstract
Health-related quality of life (HRQoL) was evaluated among red blood cell transfusion-dependent patients with
lower-risk non-del(5q) myelodysplastic syndromes (MDS) treated with lenalidomide (n [ 160) or placebo (n [
79) in the phase III MDS-005 study. Lenalidomide did not worsen HRQoL; response to lenalidomide was
associated with significant HRQoL improvement. Lenalidomide represents a treatment option for patients with
lower-risk non-del(5q) MDS who are ineligible for or refractory to erythropoiesis-stimulating agents.
Background: The phase III MDS-005 study compared lenalidomide versus placebo in red blood cell transfusion-
dependent (RBC-TD) patients with lower-risk non-del(5q) myelodysplastic syndromes (MDS), ineligible/refractory to
erythropoiesis-stimulating agents. Lenalidomide-treated patients were more likely to achieve transfusion independence
(TI) 8weeks (26.9%vs. 2.5%;P< .001) and hemoglobin increase 1.5 g/dL (19.4% vs. 2.5%) versus placebo.Patients
and Methods: Patients were randomized 2:1 to oral lenalidomide 10 mg once daily or placebo once daily (both on 28-
day cycles). Patients with creatinine clearance 40 to 60 mL/min were given lenalidomide 5 mg once daily. Health-related
quality of life (HRQoL), a predefined secondary end point, was assessed using the European Organisation for Research
and Treatment of Cancer Quality of Life QuestionnaireeCore 30 questionnaire at baseline, week 12, week 24, every 12
weeks thereafter, and at discontinuation. Results: At week 24, lenalidomide was associated with benefit versus placebo
across all 5 preselected questionnaire scales (fatigue, dyspnea, global quality of life, physical functioning, and emotional
functioning). After adjustment for baseline scores, only emotional functioning achieved significance (P ¼ .047). Further
improvement versus baseline was observed for patients who continued lenalidomide after week 24. In post hoc ana-
lyses, achievement of TI 8 weeks was associated with significant improvements across all scales (P< .01); an increase
in hemoglobin level correlated with significant improvements in all scales at week 24, except emotional functioning (P <
.05).Conclusion: Lenalidomide did not adversely affect HRQoL in RBC-TD patients with lower-risk non-del(5q) MDS and
response to lenalidomide was associated with significant improvements in HRQoL.
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higher health care costs,6,7 and poor health-related quality of life
(HRQoL).8-10 Consequently, reducing transfusion dependence and
anemia-related symptoms is the main therapeutic goal in patients with
transfusion-dependent lower-risk MDS.
Lenalidomide treatment results in RBC transfusion indepen-
dence (RBC-TI) in more than half of patients with lower-risk MDS
and del(5q),11,12 and corresponding improvements in HRQoL have
been observed.13,14 For patients without del(5q), erythropoiesis-
stimulating agents (ESAs) are the first choice treatment for ane-
mia, and response to ESAs has been associated with improved
HRQoL.15-18 However, treatment options after failure of ESAs are
limited,2 which frequently leaves anemic patients dependent on
RBC transfusions. Recently, a phase III study (MDS-005) evaluated
lenalidomide in transfusion-dependent patients with International
Prognostic Scoring System (IPSS) low- or intermediate-1 risk MDS
without del(5q) who were ineligible for or refractory to ESAs.19 In
this study, the proportion of patients who achieved RBC-TI  8
weeks was significantly higher in the lenalidomide group than in the
placebo group (26.9% vs. 2.5%; P < .001), with most responding
within 16 weeks of treatment. A higher proportion of patients in the
lenalidomide group achieved a hemoglobin increase of  1.5 g/dL
compared with the placebo group (19.4% vs. 2.5%).
Health-related quality of life was a prespecified secondary end
point of the MDS-005 study.19 This report presents detailed results
of the primary and additional post hoc analyses of patient-reported
outcomes data collected from the MDS-005 study to assess the
effect of lenalidomide treatment on HRQoL in lower-risk non-
del(5q) MDS patients.
Patients and Methods
The MDS-005 trial was a randomized, placebo-controlled,
double-blind phase III study that evaluated the efficacy and safety
of lenalidomide in patients with IPSS low- or intermediate-1 risk
MDS without del(5q) who were ineligible for or refractory to ESA
treatment. Full details of the study supporting the efficacy, safety,
and selected HRQoL findings have been published previously.19
The study was approved by individual institutional review boards
of participating centers and conducted according to the Declaration
of Helsinki. Written informed consent was obtained from all pa-
tients before enrollment. The trial was registered as NCT01029262
at https://clinicaltrials.gov.
Study Design
Eligible patients were aged 18 years or older, had transfusion-
dependent anemia (transfusion dependence was defined as an
average transfusion requirement of  2 units packed RBCs every 28
days and no 8 consecutive weeks without RBC transfusions in the
16 weeks before randomization) due to IPSS low- or intermediate-1
risk MDS, had non-del(5q) karyotype, and were ineligible for or
refractory to ESAs (defined as: [1] RBC transfusion dependence
despite ESA treatment of  40,000 units per week recombinant
human erythropoietin or equivalent dose of darbepoetin for 8
weeks; or [2] serum erythropoietin level > 500 mU/mL in patients
not previously treated with ESAs).
Patients were randomized 2:1 to oral lenalidomide 10 mg once
daily or placebo once daily (both on 28-day cycles). Patients with
creatinine clearance 40 to 60 mL/min were given lenalidomide 5 mgonce daily. Patients with RBC-TI  8 weeks or erythroid response
by week 24 continued double-blind treatment until erythroid
relapse, disease progression, unacceptable toxicity, or consent
withdrawal.
Clinical End Points
The primary clinical end point of the trial was the proportion of
patients who achieved RBC-TI for  8 consecutive weeks. Sec-
ondary clinical end points included RBC-TI  24 weeks, pro-
gression to acute myeloid leukemia, overall survival, HRQoL, and
safety.
Assessment of HRQoL
A schematic overview of the methodology used in the MDS-005
study for the assessment of HRQoL is presented in Supplemental
Figure 1 in the online version. HRQoL was assessed using the
European Organisation for Research and Treatment of Cancer
Quality of Life QuestionnaireeCore 30 (EORTC QLQ-C30)20 at
baseline, week 12, week 24, every 12 weeks thereafter, and at
discontinuation. The QLQ-C30 is a well validated and commonly
used questionnaire in MDS research.21 It consists of 30 items,
including 5 multi-item functional scales (physical, role, emotional,
social, and cognitive), 3 multi-item symptom scales (fatigue, nausea/
vomiting, and pain), a global health status/quality of life scale, and 6
single-item symptom scales (dyspnea, insomnia, appetite loss, con-
stipation, diarrhea, and financial difficulties). The standardized
scores for this questionnaire range from 0 to 100, with higher scores
indicating greater levels of functioning or more severe symptoms.
Data were collected electronically using tablet computers. All
HRQoL scales of the QLQ-C30 were analyzed; however, the
analysis focused on 5 preselected and clinically relevant scales22-25:
fatigue, dyspnea, global quality of life, physical functioning, and
emotional functioning.
Statistical Analyses
Analyses of HRQoL were based on patients in the intent-to-treat
(ITT) population who completed the baseline HRQoL assessment
and had  1 postbaseline assessment available (ie, the HRQoL-
evaluable ITT population). The statistical methods are described
in further detail in Supplemental Appendix A in the online version.
Results
Patients
From February 2010 to June 2013, 239 patients were enrolled at
72 treatment centers and randomized to lenalidomide (n ¼ 160) or
placebo (n ¼ 79), constituting the ITT population. Baseline char-
acteristics were comparable between the 2 treatment groups; overall,
the median age was 71 years (range, 43-87); 162 were male; median
time from diagnosis was 2.6 years (range, 0.1-29.6); and 118 had an
Eastern Cooperative Oncology Group score of 1 or 2. Patients had
received a median of 3.0 packed RBC units per 28 days (range,
1.5-9.8), and 200 had received previous therapy, 188 of whom
received ESAs. Overall, 122 of 160 (76.3%) patients in the lenali-
domide group and 56 of 79 (70.9%) patients in the placebo group
completed a baseline HRQoL assessment and had  1 follow-up
assessment available, thus constituting the HRQoL-evaluable ITT
population.Clinical Lymphoma, Myeloma & Leukemia February 2018 - 137
Table 1 Response Compliance Rates for the EORTC QLQ-C30
Scheduled Visit Lenalidomide Placebo P
Baseline 144/160 (90.0) 70/79 (88.6) .823
Week 12 134/160 (83.8) 62/79 (78.5) .371
Week 24a 91/106 (85.8) 50/62 (80.6) .391
Week 36 33/41 (80.5) 4/4 (100) 1.000
Week 48 23/32 (71.9) 1/2 (50.0) .508
Data are presented as n/N (%) except where otherwise stated.
Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of
Cancer Quality of Life QuestionnaireeCore 30; RBC-TI ¼ red blood cell transfusion
independence.
aOnly patients with RBC-TI  8 weeks or erythroid response by week 24 continued double-blind
treatment.
HRQoL in LEN-treated lower-risk non-del(5q) MDS
138 -Questionnaire Compliance
Response compliance rates for the HRQoL questionnaire were
high and did not differ significantly between treatment groups
across all assessment visits (P > .05; Table 1). Compliance rates for
the combined lenalidomide and placebo groups were 89.5%,
82.0%, 83.9%, 82.2%, and 70.6% at baseline and weeks 12, 24,
36, and 48, respectively. No significant differences were seen in key
baseline characteristics between compliant and noncompliant pa-
tients within each treatment group (P > .05; data not shown).
Health-Related Quality of Life Outcomes at Baseline and
Follow-up
At baseline, mean scores for each scale of the QLQ-C30 did not
differ significantly between treatment groups (see Supplemental
Table 1 in the online version). Compared with HRQoL data re-
ported for the general population,26 baseline HRQoL scores for pa-
tients in the MDS-005 study were worse, particularly for global quality
of life, physical functioning, role functioning, fatigue, dyspnea, and
constipation (see Supplemental Table 1 in the online version). At week
12, mean changes in HRQoL scores from baseline were not signifi-
cantly different between treatment groups across the 5 preselected
HRQoL scales (Figure 1). At week 24, lenalidomide was associated
with significantly less fatigue (P ¼ .046) and better emotional func-
tioning (P ¼ .035) compared with placebo (Figure 1). After week 24,
an improving trend was observed across all preselected scales in pa-
tients who continued treatment with lenalidomide; the number of
patients in the placebo group was too small to show a trend, because
most had discontinued study drug by this time point (Figure 1). No
significant difference in mean change from baseline between treatment
groups was observed for the remaining unselected scales, except for a
significant improvement in insomnia at week 24 in the lenalidomide
group compared with placebo (P ¼ .038; data not shown).
After adjusting for baseline scores, changes in HRQoL from
baseline were not significantly different between treatment groups at
week 12 (Figure 2). At week 24, only change in emotional func-
tioning was statistically significant (þ 0.8 with lenalidomide vs. 7.1
with placebo; P ¼ .047) in the preselected scales; however, no
adjustment for multiplicity was performed. In the remaining unse-
lected scales, lenalidomide was associated with a significant improve-
ment in insomnia (P ¼ .004) and a significant worsening in diarrhea
(P ¼ .050) at week 24 compared with placebo (data not shown).
Differences in predicted least-squares mean changes in HRQoL
scores at week 24 for the preselected scales are shown in Figure 3.Clinical Lymphoma, Myeloma & Leukemia February 2018Lenalidomide was associated with better HRQoL scores versus
placebo across all preselected scales, particularly fatigue, dyspnea,
and emotional functioning. None of the scales reached statistical
significance, possibly due to small sample size. The analyses were
not adjusted for the imputation of missing data; however, our an-
alyses were consistent with results of analyses using complete cases,
last observation carried forward, and pattern mixture approaches to
imputing missing data.
The proportion of patients in the lenalidomide and placebo
groups categorized as having clinically meaningful improvement or
worsening in preselected HRQoL scales at week 24 is shown in
Figure 4. For each scale, the lenalidomide group had a larger pro-
portion of patients with clinically meaningful improvement and a
smaller proportion with clinically meaningful worsening compared
with placebo, although the difference between groups was not sta-
tistically significant for any of the scales.
Relationship Between Achievement of RBC-TI  8 Weeks
Response and Changes in HRQoL Outcomes
In a post hoc analysis based on HRQoL-evaluable patients who
completed a baseline HRQoL assessment and  1 postbaseline
assessment (lenalidomide, n ¼ 134; placebo, n ¼ 62), achievement
of RBC-TI  8 weeks (n ¼ 41) was associated with a significant
improvement (P < .01) in HRQoL across all preselected scales
(Figure 5).19 The benefit associated with RBC-TI  8 weeks
exceeded the prespecified score difference of  10 points versus
baseline for clinically meaningful improvement in all 5 scales.
In another post hoc analysis, changes in HRQoL from baseline
for the 5 preselected scales were not significantly different between
lenalidomide nonresponders (ie, lenalidomide-treated patients who
did not achieve RBC-TI  8 weeks) and placebo patients, sug-
gesting that lenalidomide treatment even in the absence of a
response had no significant negative effect on HRQoL. However,
lenalidomide responders (ie, those who achieved RBC-TI  8
weeks) did show improvements in all 5 scales compared with
lenalidomide nonresponders or placebo patients. This suggests that
patients who responded to lenalidomide therapy not only benefitted
in terms of becoming RBC-TI, but also experienced a significant
alleviation of patient-reported symptoms (see Supplemental
Figure 2 in the online version). The incidence of common Grade
3/4 adverse events was comparable between RBC-TI  8 weeks
responders and nonresponders (see Supplemental Table 2 in the
online version).
Relationship Between Change in Hemoglobin Level and
Changes in HRQoL Outcomes
In a post hoc analysis of the lenalidomide and placebo groups
combined, change in hemoglobin level from baseline correlated
significantly (P < .05) with changes in HRQoL across all scales and
time points, except for emotional functioning at weeks 12 and 24
and dyspnea at week 12 (Table 2). Hemoglobin level correlated
positively with functional scales and negatively with symptom scales.
The strength of the correlation increased from week 12 to week 24.
Discussion
This study provides the first detailed analysis of HRQoL from a
randomized, placebo-controlled phase III study of lenalidomide in
Figure 1 Mean Change From Baseline in HRQoL Scores Without Adjusting for Baseline Scores for Preselected EORTC QLQ-C30 Scales:
(A) Fatigue, (B) Dyspnea, (C) Global Quality of Life, (D) Physical Functioning, and (E) Emotional Functioning, According to
Randomized Treatment Group. * Significant Difference (P < .05) Between Treatment Groups. yData for Placebo Group at









































































































































































































































































Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life; SE ¼ standard error.
Valeria Santini et alRBC transfusion-dependent patients with lower-risk, non-del(5q)
MDS who were ineligible for or refractory to ESAs. Overall,
treatment with lenalidomide did not worsen HRQoL compared
with placebo, and clinically meaningful improvements were
observed at week 24 in a proportion of patients, with a trend toward
sustained improvements when lenalidomide treatment was extendedbeyond 24 weeks. Notably, response to lenalidomide was associated
with significant improvements in HRQoL.
Anemia is the most common cause of symptoms in patients with
lower-risk MDS,1 and anemia-related fatigue can negatively affect
HRQoL.27,28 Dependence on RBC transfusions is also associated
with worse HRQoL8,9 and significantly shorter survival.4,5 InClinical Lymphoma, Myeloma & Leukemia February 2018 - 139
Figure 2 Mean Change From Baseline in HRQoL Scores After Adjusting for Baseline Scores for Preselected EORTC QLQ-C30 Scales




































































P = .047 























Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life.
HRQoL in LEN-treated lower-risk non-del(5q) MDS
140 -addition, self-reported fatigue severity strongly correlates with
patient-perceived symptom severity29 and might provide prognostic
information for overall survival independent of standard riskFigure 3 Difference in Predicted Least-Squares Mean Changes for P
Versus Placebo at Week 24. The Model Included the Follo























































Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Q
Clinical Lymphoma, Myeloma & Leukemia February 2018assessment in patients with higher-risk MDS.30 Achievement of
RBC-TI during lenalidomide therapy was associated with significant
improvements in HRQoL. Our findings showed that an increase inreselected EORTC QLQ-C30 HRQoL Scales Between Lenalidomide
wing Covariates: Treatment Group, Time (in Weeks), Baseline























uality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life.
Figure 4 Proportion of Patients With Clinically Meaningful Improvement or Worsening in Scores for Preselected EORTC QLQ-C30
HRQoL Scales at Week 24. A Clinically Meaningful Change Was Defined as a Change of ‡ 10 Points From Baseline
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Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life.
Valeria Santini et alhemoglobin level positively affected HRQoL, and the effect
appeared to increase over time. These observations are consistent
with previous reports on the effect of hemoglobin level and RBC
transfusion dependence on HRQoL in MDS.8,9,31
Other studies of lenalidomide in lower-risk MDS have also re-
ported positive effects on HRQoL.13,14,32 In a phase III study of
lower-risk MDS patients with del(5q), scores for the Functional
Assessment of Cancer TherapyeAnemia scale improved signifi-
cantly from baseline in patients treated with lenalidomide 5 mg and
10 mg (þ 5.7 and þ 5.7, respectively) versus placebo ( 2.8; both
P < .05).13 Improvements were significantly greater in patients who
achieved transfusion independence. The HRQoL benefit was
apparent after 12 weeks in this patient population with del(5q)
MDS. Continued treatment with lenalidomide was associated with
further benefits. Similarly, a single-arm phase II trial of patients with
anemia and lower-risk del(5q) MDS reported that erythroid
response with lenalidomide was associated with significant im-
provements in several scales of the MDS-specific QOL-E ques-
tionnaire compared with nonresponders.32 Recent findings further
suggest that transfusion-independent patients with lower-risk
del(5q) MDS and moderate levels of anemia might also benefit
from early treatment with lenalidomide in terms of better physical
functioning.14 Our study has found that the HRQoL benefits of
lenalidomide in lower-risk MDS are not just restricted to patients
with the del(5q) karyotype.
The observed improvements in HRQoL are consistent with the
known biological and clinical effects of lenalidomide in lower-riskMDS.11,12,19,33-35 In a phase II study of transfusion-dependent
patients with del(5q), 67% of patients treated with lenalidomide
achieved RBC-TI  8 weeks, with a median peak increase in
hemoglobin level of 5.4 g/dL.11 In a subsequent phase III study,
significantly more patients treated with lenalidomide 5 mg and
10 mg achieved RBC-TI  26 weeks compared with placebo
(42.6% and 56.1%, respectively, vs. 5.9%; both P < .001).12 In
the MDS-005 phase III study of non-del(5q) lower-risk patients,
lenalidomide resulted in RBC-TI  8 weeks in 26.9% of
patients,19 which was consistent with the response rate observed in
the initial phase II MDS-002 trial.33 Myelosuppression is a
common adverse event observed in patients treated with lenali-
domide: in MDS-005, the incidence of Grade 3/4 neutropenia
and thrombocytopenia was 62% and 36%, respectively.19 The
incidence of common Grade 3/4 adverse events was comparable
between responders and nonresponders. In contrast to previous
findings in patients with del(5q) from the MDS-003 study,36
lenalidomide-induced myelosuppression occurring early during
treatment did not predict response to lenalidomide in patients
with non-del(5q) MDS in the present study (data not shown). In
our analysis, achievement of RBC-TI  8 weeks was nevertheless
associated with improved HRQoL. This suggests that, overall, in
terms of HRQoL, the positive effects of achieving transfusion
independence might outweigh the negative effects of adverse
events associated with treatment.
Whereas improvements in HRQoL were observed after 12 weeks
of lenalidomide treatment in patients with del(5q),13 our analysis ofClinical Lymphoma, Myeloma & Leukemia February 2018 - 141
Figure 5 Relationship Between Achievement of RBC-TI ‡ 8 Weeks and Change in HRQoL. For Each EORTC QLQ-C30 Scale, the Effect of
RBC-TI ‡ 8 Weeks Achievement on HRQoL Was Adjusted for Other Relevant Covariates, Including Baseline Score, Time









































































Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life; RBC-TI ¼ red blood
cell transfusion independence.
Reproduced with permission from Santini et al. Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic
syndromes and ineligible for or refractory to erythropoiesis-stimulating agents. J Clin Oncol 2016; 34:2988-96.19
Table 2 Relationship Between Change From Baseline in
Hemoglobin Level and Changes in HRQoL Outcomes
for the Combined Lenalidomide and Placebo Groups
in Patients With Available Hemoglobin and HRQoL








Fatigue Week 12 131 0.24042 .0057
Week 24 92 0.45423 <.0001
Dyspnea Week 12 131 0.13084 .1363
Week 24 92 0.21807 .0368
Functional Scales
Global quality of life Week 12 131 0.21277 .0147
Week 24 92 0.32566 .0015
Physical functioning Week 12 131 0.19409 .0263
Week 24 92 0.55735 <.0001
Emotional functioning Week 12 131 0.09999 .2558
Week 24 92 0.20479 .0502
Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of
Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life.
HRQoL in LEN-treated lower-risk non-del(5q) MDS
142 -a non-del(5q) population showed that the HRQoL benefit was
delayed until week 24 of treatment. This observation is consistent
with the longer median time to onset of RBC-TI in non-del(5q)
patients compared with del(5q) patients.12,19 The reported
HRQoL benefits we observed, together with the possibility of
selecting patients more likely to respond to lenalidomide based on
endogenous erythropoietin level,19 is encouraging in this ESA-
refractory or -ineligible group with otherwise very limited treat-
ment options. Furthermore, the combination of lenalidomide and
erythropoietin37 has been added to the updated National
Comprehensive Cancer Network guidelines as a treatment option
for patients with lower-risk non-del(5q) MDS who fail to respond
or stop responding to ESAs.38
A potential limitation of the current study is that only patients
who achieved RBC-TI  8 weeks or erythroid response were
allowed to continue treatment after week 24. The small number
of patients in this group precludes comparisons of HRQoL be-
tween treatment groups beyond week 24. However, the available
data after week 24 (in responding patients) suggest continued
positive effects of long-term treatment with lenalidomide in terms
of HRQoL. Questionnaire-based studies are subject to selection
bias due to study dropout and patient-related factors, such as
older age and higher level of comorbidity.39 However, despite theClinical Lymphoma, Myeloma & Leukemia February 2018
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Valeria Santini et alelderly patient population and electronic method of data collec-
tion, compliance rates in this study were high and similar between
treatment groups at all assessment visits. Baseline characteristics
of compliant and noncompliant patients were comparable, sug-
gesting that the data are representative of all patients in the MDS-
005 study and the results are unlikely to be affected by dropouts.
Notably, imputation using different methods and missing data
assumptions produced consistent results, indicating that bias due
to missing data is unlikely. Our results add to the existing evi-
dence showing the utility of the QLQ-C30 in patients with
MDS.29,40,41
Conclusion
Treatment with lenalidomide did not worsen HRQoL overall
compared with placebo in patients with lower-risk non-del(5q)
MDS, regardless of responder status. Achievement of RBC-TI  8
weeks during lenalidomide therapy was associated with significant
improvements in HRQoL. Continued lenalidomide treatment
appeared to maintain or increase improvements in HRQoL. Based
on these findings and the results of the MDS-005 trial, lenalidomide
represents a treatment option for patients with lower-risk non-
del(5q) MDS who are ineligible for or refractory to ESAs, and
optimal benefit may be attained when treatment is maintained after
achievement of RBC-TI.
Clinical Practice Points
 Transfusion-dependent MDS is associated with poor HRQoL
due to anemia-related fatigue and the burden of undergoing
chronic transfusions.
 In the MDS-005 phase III study of patients with non-del(5q)
lower-risk MDS, 26.9% of patients achieved RBC-TI  8
weeks with lenalidomide treatment. Until this analysis, however,
the effect of lenalidomide on patient HRQoL in this setting was
relatively unclear.
 Our study shows that HRQoL did not worsen during lenali-
domide treatment, and patients who responded to lenalidomide
reported significant improvements in HRQoL. Continued
lenalidomide treatment appeared to maintain or increase im-
provements in HRQoL.
 First, these findings highlight the importance of achieving RBC-
TI in patients with lower-risk MDS, as this was associated with a
significant improvement in patient HRQoL. Achievement of
transfusion independence should therefore remain an important
goal of therapy for these patients.
 Second, our findings further support the use of lenalidomide in
patients with lower-risk non-del(5q) MDS who are refractory to
ESAs. Because of the limited treatment options currently avail-
able for these patients, the use of lenalidomide in selected pa-
tients might help improve patient outcomes, including HRQoL.Acknowledgments
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Additional Methods: Statistical Analyses
The proportion of patients completing the EORTC QLQ-C30
was calculated at each assessment visit. A patient was considered
compliant at a particular visit if  15 of 30 questionnaire items were
completed. The denominator for each visit was calculated on the
basis of the number of patients who were still receiving the study
drug at that time point. The 2-sided Fisher exact test was used to
compare the proportion of compliant patients at each assessment
visit between treatment groups. Key baseline characteristics between
compliant and noncompliant patients were compared between
treatment groups using the 2-sided Fisher exact test for categorical
variables and the 2-sample t test for continuous variables.
For each scale of the QLQ-C30, descriptive statistics of observed
scores and change from baseline scores were calculated for each visit.
A pooled, 2-sample, 2-sided t test was used to determine differences
in mean changes from baseline between treatment groups. Between-
group comparisons were limited to weeks 12 and 24 because of low
patient numbers after 24 weeks. To account for differences in
baseline scores between treatment groups, analysis of variance was
also performed on change from baseline scores in preselected
HRQoL scales between treatment groups. Sensitivity analyses using
last observation carried forward, complete-case analysis, and pattern
mixture model were performed to assess the effect of missing data
on the primary analyses.
To estimate the effect of treatment on each scale of the QLQ-
C30 over time and assess differences between treatment groups, a
linear mixed effects repeated measures analysis model with random
intercept/slope was used, using a restricted maximum likelihood
estimation method. The following covariates were included:Supplemental Figure 1 Assessment of HRQoL in the MDS-005 Stud
Abbreviations: HRQoL ¼ health-related quality of life; LEN ¼ lenalidomide; MDS ¼ myelodysplastictreatment group, time (in weeks), baseline score, and a Treatment
group  Time interaction term, with intercept and time as
random effects. Results were summarized using the least squares
means for change from baseline to week 24 within each treatment
group and the difference in least squares means between treatment
groups.
Clinically meaningful changes in HRQoL scale scores were pre-
specified as a score difference of  10 points versus baseline.1 Pa-
tients were accordingly grouped into categories of improvement, no
change, or worsening. The 2-sided Fisher exact test was used to
compare the proportions of patients within these categories at each
postbaseline visit between treatment groups.
A post hoc analysis was performed to assess the effect of RBC-TI,
as a time-varying covariate while controlling for other significant
factors, on preselected HRQoL scales using a linear mixed-effects
regression model to estimate the difference in scores between RBC-
TI  8 weeks responders and nonresponders. The incidence of
Grade 3/4 adverse events was analyzed according to RBC-TI  8
weeks response in lenalidomide-treated patients. Adverse events
were coded as in the Medical Dictionary for Regulatory Activities
and graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (version 3.0). In addition,
a post hoc analysis was conducted to assess the relationship between
change in hemoglobin level and changes in HRQoL outcomes at
weeks 12 and 24 across all 5 preselected scales. The postbaseline
hemoglobin collection dates were matched with the HRQoL as-
sessments to obtain hemoglobin data on the same day as the
HRQoL visit. The association between variables was analyzed using
the Pearson correlation coefficient.
The data cutoff date for inclusion in this analysis was March
17, 2014.y
syndromes; RBC-TI ¼ red blood cell transfusion independence.
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Supplemental Figure 2 Mean Change From Baseline in HRQoL Scores Without Adjusting for Baseline Scores for Preselected EORTC
QLQ-C30 Scales (A: Fatigue, B: Dyspnea, C: Global Quality of Life, D: Physical Functioning, E: Emotional
Functioning) in Lenalidomide Responders, Lenalidomide Nonresponders, and Placebo Patients. *P < .05 for
the Comparison of Lenalidomide Responders Versus Lenalidomide Nonresponders; Lenalidomide
Nonresponders Versus Placebo; Lenalidomide Responders Versus Placebo
Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life; SE ¼ standard error.
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Supplemental Table 1 Mean Scores of EORTC QLQ-C30
Scales at Baseline Among HRQoL-
Evaluable Patients From the MDS-005
Study (Lenalidomide and Placebo










Global Quality of Life 57.1 (21.96) 59.9 (17.27) 71.2 (22.4)
Physical Functioning 69.6 (20.95) 73.1 (17.35) 89.8 (16.2)
Role Functioning 68.8 (30.48) 74.7 (25.02) 84.7 (25.4)
Emotional Functioning 76.8 (21.27) 78.7 (20.72) 76.3 (22.8)
Cognitive Functioning 83.5 (19.99) 88.2 (14.65) 86.1 (20.0)
Social Functioning 80.0 (23.79) 82.5 (21.04) 87.5 (22.9)
Fatigue 42.8 (26.23) 37.5 (20.37) 24.1 (24.0)
Nausea/Vomiting 4.1 (10.36) 5.7 (12.70) 3.7 (11.7)
Pain 21.9 (29.89) 21.3 (26.27) 20.9 (27.6)
Dyspnea 30.3 (30.51) 31.6 (29.57) 11.8 (22.8)
Insomnia 27.7 (30.7) 27.0 (31.50) 21.8 (29.7)
Appetite Loss 15.5 (27.21) 8.6 (15.99) 6.7 (18.3)
Constipation 17.0 (26.59) 15.5 (23.54) 6.7 (18.4)
Diarrhea 9.7 (21.28) 8.0 (18.00) 7.0 (18.0)
Financial Difficulties 13.2 (25.38) 15.5 (24.36) 9.5 (23.2)
Data are presented as mean score (SD). A clinically meaningful change was defined as a
change of  10 points from baseline.
Abbreviations: EORTC QLQ-C30 ¼ European Organisation for Research and Treatment of
Cancer Quality of Life QuestionnaireeCore 30; HRQoL ¼ health-related quality of life.
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Supplemental Table 2 Grade 3/4 TEAEs in Lenalidomide-Treated Patients According to RBC-TI ‡8 Weeks Response
Adverse Event
Lenalidomide Placebo
RBC-TI ‡ 8 Weeks
Responders
(n [ 43)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 117)
RBC-TI ‡ 8 Weeks
Responders
(n [ 2)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 77)
Patients With ‡ 1 Grade 3/4 TEAE 39 (90.7) 99 (84.6) 1 (50.0) 34 (44.2)
Blood and Lymphatic System Disorders 37 (86.0) 81 (69.2) 1 (50.0) 16 (20.8)
Neutropenia 35 (81.4) 64 (54.7) 0 9 (11.7)
Thrombocytopenia 15 (34.9) 42 (35.9) 0 3 (3.9)
Leukopenia 10 (23.3) 8 (6.8) 0 1 (1.3)
Anemia 2 (4.7) 7 (6.0) 0 4 (5.2)
Bone marrow reticulin fibrosis 0 1 (0.9)
Coagulopathy 0 1 (0.9)
Hemolysis 0 1 (0.9)
Pancytopenia 0 1 (0.9)
Febrile neutropenia 1 (2.3) 0 1 (50.0) 0
Lymphopenia 1 (2.3) 0
Infections and Infestations 4 (9.3) 19 (16.2) 0 3 (3.9)
Pneumonia 3 (7.0) 6 (5.1) 0 2 (2.6)
Neutropenic sepsis 0 3 (2.6)
Urinary tract infection 0 2 (1.7) 0 1 (1.3)
Atypical pneumonia 0 1 (0.9)
Bronchitis 0 1 (0.9)
Bronchopneumonia 0 1 (0.9)
Cellulitis 0 1 (0.9)
Escherichia sepsis 0 1 (0.9)
Folliculitis 0 1 (0.9)
Parotitis 0 1 (0.9)
Peritonitis bacterial 0 1 (0.9)
Pneumonia viral 0 1 (0.9)
Staphylococcal infection 0 1 (0.9)
Tooth abscess 0 1 (0.9)
Lobar pneumonia 1 (2.3) 0
Influenza 0 1 (1.3)
General Disorders and Administration-
Site Conditions
4 (9.3) 11 (9.4) 0 2 (2.6)
Asthenia 1 (2.3) 5 (4.3) 0 1 (1.3)
Fatigue 1 (2.3) 4 (3.4) 0 1 (1.3)
Face edema 0 1 (0.9)
Edema peripheral 0 1 (0.9)
General physical health deterioration 1 (2.3) 0
Malaise 1 (2.3) 0
Investigations 4 (9.3) 10 (8.5) 0 4 (5.2)
Liver function test abnormal 0 2 (1.7)
Alanine aminotransferase increased 2 (4.7) 1 (0.9) 0 1 (1.3)
Blood bilirubin increased 0 1 (0.9)
Blood creatinine increased 0 1 (0.9)
Blood glucose increased 0 1 (0.9)
C-reactive protein increased 0 1 (0.9)
HLA marker study positive 0 1 (0.9)
Mycobacterium test positive 0 1 (0.9)
Oxygen saturation decreased 0 1 (0.9)
HRQoL in LEN-treated lower-risk non-del(5q) MDS
144.e4 - Clinical Lymphoma, Myeloma & Leukemia February 2018
Supplemental Table 2 Continued
Adverse Event
Lenalidomide Placebo
RBC-TI ‡ 8 Weeks
Responders
(n [ 43)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 117)
RBC-TI ‡ 8 Weeks
Responders
(n [ 2)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 77)
Troponin increased 0 1 (0.9) 0 1 (1.3)
Aspartate aminotransferase increased 1 (2.3) 0
Weight decreased 1 (1.3) 0 0 1 (1$3)
Gamma-glutamyltransferase increased 0 1 (1.3)
Serum ferritin increased 0 1 (1.3)
Metabolism and Nutrition Disorders 2 (4.7) 10 (8.5) 0 5 (6.5)
Hypokalemia 1 (2.3) 6 (5.1)
Decreased appetite 0 1 (0.9)
Hyperglycemia 0 1 (0.9)
Hyperkalaemia 0 1 (0.9)
Hypocalcemia 0 1 (0.9)
Iron overload 1 (2.3) 1 (0.9) 0 2 (2.6)
Fluid overload 0 1 (1.3)
Hyperuricemia 0 1 (1.3)
Hypoglycemia 0 1 (1.3)
Gastrointestinal Disorders 1 (2.3) 8 (6.8) 0 4 (5.2)
Diarrhea 0 4 (3.4)
Abdominal pain 0 1 (0.9) 0 1 (1.3)
Ascites 0 1 (0.9)
Gastrointestinal necrosis 0 1 (0.9)
Hematemesis 0 1 (0.9)
Nausea 0 1 (0.9)
Inguinal hernia, obstructive 1 (2.3) 0
Constipation 0 2 (2.6)
Diverticulum 0 1 (1.3)
Pancreatitis 0 1 (1.3)
Pancreatitis, necrotizing 0 1 (1.3)
Skin and Subcutaneous Tissue Disorders 3 (7.0) 8 (6.8) 0 2 (2.6)
Drug eruption 0 1 (0.9)
Dry skin 0 1 (0.9)
Exfoliative rash 0 1 (0.9)
Neurodermatitis 0 1 (0.9)
Pruritus 2 (4.7) 1 (0.9) 0 2 (2.6)
Rash erythematous 0 1 (0.9)
Rash pruritic 0 1 (0.9)
Skin ulcer 1 (2.3) 1 (0.9)
Urticaria 0 1 (0.9)
Rash, other 1 (2.3) 0
Respiratory, Thoracic, and Mediastinal
Disorders
1 (2.3) 7 (6.0) 0 3 (3.9)
Dyspnea 0 3 (2.6) 0 3 (3.9)
Pleural effusion 0 2 (1.7)
Acute respiratory distress syndrome 0 1 (0.9)
Epistaxis 0 1 (0.9)
Hypoxia 0 1 (0.9)
Lung disorder 0 1 (0.9)
Asthma 1 (2.3) 0
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Adverse Event
Lenalidomide Placebo
RBC-TI ‡ 8 Weeks
Responders
(n [ 43)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 117)
RBC-TI ‡ 8 Weeks
Responders
(n [ 2)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 77)
Cardiac Disorders 0 6 (5.1) 0 5 (6.5)
Cardiac failure 0 2 (1.7) 0 1 (1.3)
Myocardial infarction 0 2 (1.7) 0 1 (1.3)
Atrial fibrillation 0 1 (0.9) 0 3 (3.9)
Cardiac failure congestive 0 1 (0.9)
Atrial flutter 0 1 (1.3)
Ventricular arrhythmia 0 1 (1.3)
Neoplasms Benign, Malignant, and
Unspecified (Including Cysts and Polyps)
1 (2.3) 4 (3.4) 0 5 (6.5)
Myelodysplastic syndromes 0 2 (1.7)
Adenocarcinoma of colon 0 1 (0.9)
Lung squamous cell carcinoma stage IV 0 1 (0.9)
Invasive ductal breast carcinoma 1 (2.3) 0
Acute myeloid leukemia 0 2 (2.6)
Chronic myelomonocytic leukemia 0 1 (1.3)
Prostate cancer 0 1 (1.3)
Squamous cell carcinoma of lung 0 1 (1.3)
Musculoskeletal and Connective Tissue
Disorder
0 3 (2.6) 0 1 (1.3)
Intervertebral disc protrusion 0 1 (0.9)
Osteoarthritis 0 1 (0.9)
Pain in jaw 0 1 (0.9)
Rhabdomyolysis 0 1 (1.3)
Nervous System Disorders 0 3 (2.6)
Headache 0 1 (0.9)
Lethargy 0 1 (0.9)
Syncope 0 1 (0.9)
Vascular Disorders 2 (4.7) 3 (2.6) 0 1 (1.3)
Deep vein thrombosis 1 (2.3) 2 (1.7)
Circulatory collapse 0 1 (0.9) 0 1 (1.3)
Hypotension 1 (2.3) 0
Hepatobiliary Disorders 0 2 (1.7) 0 2 (2.6)
Hepatic cirrhosis 0 1 (0.9) 0 1 (1.3)
Hepatic failure 0 1 (0.9)
Hyperbilirubinemia 0 1 (0.9) 0 1 (1.3)
Jaundice 0 1 (0.9)
Biliary colic 0 1 (1.3)
Injury, Poisoning, and Procedural
Complications
4 (9.3) 2 (1.7)
Femoral neck fracture 0 1 (0.9)
Hip fracture 0 1 (0.9)
Femur fracture 2 (4.7) 0
Lumbar vertebral fracture 1 (2.3) 0
Thoracic vertebral fracture 1 (2.3) 0
Traumatic intracranial hemorrhage 1 (2.3) 0
Renal and Urinary Disorders 2 (4.7) 2 (1.7)
Pollakiuria 0 1 (0.9)
Renal failure acute 0 1 (0.9)
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Adverse Event
Lenalidomide Placebo
RBC-TI ‡ 8 Weeks
Responders
(n [ 43)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 117)
RBC-TI ‡ 8 Weeks
Responders
(n [ 2)
RBC-TI ‡ 8 Weeks
Nonresponders
(n [ 77)
Nephrolithiasis 1 (2.3) 0
Renal colic 1 (2.3) 0
Renal failure chronic 1 (2.3) 0
Ear and Labyrinth Disorders 0 1 (0.9)
Middle ear inflammation 0 1 (0.9)
Psychiatric Disorders 2 (4.7) 0 0 2 (2.6)
Confusional state 1 (2.3) 0 0 1 (1.3)
Insomnia 1 (2.3) 0
Mental status changes 1 (2.3) 0
Anxiety 0 1 (1.3)
Data are presented as n (%).
Abbreviations: HLA ¼ human leukocyte antigen; RBC-TI ¼ red blood cell transfusion independence; TEAE ¼ treatment-emergent adverse event.
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